Electromed authorizes $10 million share repurchase program

Electromed Inc. (NYSE American: ELMD) announced that its board of directors authorized the company to repurchase up to $10 million of common stock on September 9, 2025. The medical device company said this authorization follows the completion of its previous share repurchase program in the fourth quarter of fiscal 2025.

The New Prague, Minnesota-based company said the timing and amount of share repurchases will be determined by management based on market conditions and other considerations. Repurchases may occur through open market transactions at prevailing market prices, privately negotiated transactions, block trades, or other legally permissible methods.

"Underpinning the decision to repurchase shares is Electromed's strong operational performance and robust cash reserves," said Jim Cunniff, the company's president and chief executive officer. He added that the authorization reflects the company's commitment to enhancing shareholder value over the long term.

The board of directors will review the share repurchase program periodically and may authorize adjustments to its terms and size, according to the company's statement.

Electromed manufactures and markets airway clearance therapy products, including the SmartVest Airway Clearance System, for patients with compromised pulmonary function. The company was founded in 1992 and is headquartered in New Prague, Minnesota.

You May Also Be Interested In